In April 2014, Novartis divested its consumer health section with $3.5 billion worth of assets into a new joint venture with GlaxoSmithKline, named GSK Consumer Healthcare, of which Novartis will hold a 36.5% stake. In March 2018, GSK announced that it has reached an agreement with Novartis to acquire Novartis' 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion (£9.2 billion).
In April 2014 Novartis divested its consumer health section with $35 billion worth of assets into a new joint venture with GlaxoSmithKline named GSK Consumer Healthcare of which Novartis will hold a 365% stake In March 2018 GSK announced that it has reached an agreement with Novartis to acquire Novartis' 365% stake in their Consumer Healthcare Joint Venture for $13 billion (£92 billion)